EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 3.0

Semaglutide Reduces Cardiomyocyte Damage Caused by High-Fat Through HSDL2

Lin Yang, Xiaoyu Pan, Zhenyu Pan, Haina Gao, Jiangli Ban, Shuchun Chen

Drug Design, Development and Therapy · 2024

DOI: 10.2147/dddt.s495659 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Drug Design, Development and Therapy, 2024. Verfasst von Lin Yang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Hebei North University, Zhangjiakou, Hebei, People's Republic of China. Hauptthemen laut MEDLINE: Myocytes, Cardiac, Diet, High-Fat, Glucagon-Like Peptides, Oxidative Stress. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Myocytes, CardiacDiet, High-FatGlucagon-Like PeptidesOxidative StressMice, Inbred C57BLAnimalsMiceMaleCells, CulturedMice, KnockoutObesityDisease Models, AnimalSemaglutide

Stichwörter der Autor:innen

HSDL2inflammationobesityoxidative stresssemaglutide

Substanzen

Glucagon-Like PeptidesSemaglutide

Autor:innen und Institutionen

  • Department of Internal Medicine, Hebei North University, Zhangjiakou, Hebei, People's Republic of China.
  • Department of Endocrinology, Hebei General Hospital, Shijiazhuang, Hebei, People's Republic of China.
  • Department of Internal Medicine, Shandong Medical College, Linyi, Shandong, People's Republic of China.
  • Department of Endocrinology, The Second Hospital of Shijiazhuang, Shijiazhuang, Hebei, People's Republic of China.
  • Department of Internal Medicine, Hebei Medical University, Shijiazhuang, Hebei, People's Republic of China.
  • Hebei Key Laboratory of Metabolic Diseases, Hebei General Hospital, Shijiazhuang, Hebei, People's Republic of China.

Zitieren

APA

Yang, L., Pan, X., Pan, Z., Gao, H., Ban, J., & Chen, S. (2024). Semaglutide Reduces Cardiomyocyte Damage Caused by High-Fat Through HSDL2. Drug Design, Development and Therapy. https://doi.org/10.2147/dddt.s495659

Vancouver

Yang L, Pan X, Pan Z, Gao H, Ban J, Chen S. Semaglutide Reduces Cardiomyocyte Damage Caused by High-Fat Through HSDL2. Drug Design, Development and Therapy. 2024. doi:10.2147/dddt.s495659

BibTeX
@article{Yang2024,
  author = {Yang, Lin and Pan, Xiaoyu and Pan, Zhenyu and Gao, Haina and Ban, Jiangli and Chen, Shuchun},
  title = {Semaglutide Reduces Cardiomyocyte Damage Caused by High-Fat Through HSDL2},
  journal = {Drug Design, Development and Therapy},
  year = {2024},
  doi = {10.2147/dddt.s495659}
}
Kostenlos starten →